This program ensures that employees have affordable copay access to medications, receive physician-guided treatment, and gain access to nutrition support
Adolescent substance abuse: A public health priority
Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Members who engage with their coach or community in the first week of their Omada program are 24% more likely to be engaged at month four versus those who didnt have the same social interactions
Eli Lilly and Novo Nordisk did not immediately respond to Reuters requests for comment.
[DOI] [PubMed] [Google Scholar] 530.Westermark P., Wilander E
.webp)
